The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability,
Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single
intravenous (IV) infusion to patients with lymphoid malignancies.